Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03994822 · ClinicalTrials.gov registry record · NA
pRESET for Occlusive Stroke Treatment
A NA study of Cardiovascular Diseases and Vascular Diseases, sponsored by phenox.
- Completed
- Registry status
- NA
- Development phase
- 340
- Enrollment target
- 20
- Study locations
NCT03994822: Completed NA study of Cardiovascular Diseases and Vascular Diseases, sponsored by phenox.
NCT03994822 is a NA study of Cardiovascular Diseases and Vascular Diseases that has completed, run by phenox. The registered enrollment target is 340 participants, below the 26,973-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03994822, a NA study of Cardiovascular Diseases and Vascular Diseases, has completed, sponsored by phenox.
- COMPLETED
- Registry status
- NA
- Development phase
- 340 participants
- Enrollment target
- 20
- Study locations
Study Summary
Compare the safety and effectiveness of pRESET to Solitaire in the treatment of stroke related to large vessel occlusion
Primary Outcome
Global disability assessed via the blinded evaluation of the proportion of patients with a Modified Rankin Scale (mRS) \</= 2
Conditions Studied
Interventions
- DEVICE Mechanical Thrombectomy using the pRESET Thrombectomy device
- DEVICE Mechanical Thrombectomy using the Solitaire Revascularization Device
Study Locations (20)
New York
- Buffalo General Medical Center - Buffalo
- NYU Langone Health - New York
- The Mount Sinai Hosptial - New York
- Montefiore Medical Center - The Bronx
Florida
- University of Miami - Coral Gables
- Baptist Health Research Institute Jacksonville - Jacksonville
Illinois
- Rush University Medical Center - Chicago
- Advocate Lutheran General Hospital - Downers Grove
Arizona
- Honor Health Research Institute - Scottsdale
California
- Providence Little Company of Mary Medical Center - Santa Monica
Georgia
- Grady Memorial Hospital - Atlanta
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Massachusetts
- University of Massachusetts - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2019-10-04 |
| Est. Completion | 2022-05-12 |
| Phase | NA |
What the finished NCT03994822 record still lists
NCT03994822 is an interventional study that assigns participants to a tested intervention. The registered 340 participants enrollment target is mid-sized for trials with a published cap, below the 26,973-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (99% lower).
The record links to 10 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 2 interventions - of which Mechanical Thrombectomy using the pRESET Thrombectomy device is the first listed.
NCT03994822 names 20 study sites across 15 states, led by New York, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT03994822 about?
NCT03994822 is a clinical study titled "pRESET for Occlusive Stroke Treatment". Compare the safety and effectiveness of pRESET to Solitaire in the treatment of stroke related to large vessel occlusion
What is the current status of trial NCT03994822?
This trial is currently completed. It is a NA study. The enrollment target is 340 participants. The study started on 2019-10-04. Estimated completion is 2022-05-12.
What conditions does trial NCT03994822 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Vascular Diseases, Stroke, Ischemic, Stroke, Acute, Nervous System Diseases.
What interventions are being tested in trial NCT03994822?
The interventions under investigation include: Mechanical Thrombectomy using the pRESET Thrombectomy device (DEVICE), Mechanical Thrombectomy using the Solitaire Revascularization Device (DEVICE).
Who is sponsoring clinical trial NCT03994822?
This trial is sponsored by phenox, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03994822 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03994822's enrollment target sits among peer trials
340 115th of 300 higher than 184 of 300 other Cardiovascular Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Influence of Chardonnay Marc Intake on Gut and Cardiometabolic Health
RECRUITING · NA
-
Identifying Strategies to Reduce Cardiovascular Risk Among Mothers of Young Children
RECRUITING · NA
-
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
RECRUITING · NA
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04176172 · 340 participants · Phase 3
Optimizing Tobacco Use Treatment for PLWHA
- NCT04545424 · 340 participants · Phase 2
Trial of Therapeutic Hypothermia in Patients With ARDS
- NCT05323409 · 340 participants · NA
Improving Comprehensive Care of Cancer Patients
- NCT05388864 · 340 participants · NA
Building Resilient Families
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI